Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887235 | 0.83 | KMT2A (0.48) | PTPN1KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL7603248 | 0.80 | MAPT (0.50) | KMT2AALDH1A1HSD17B10TDP1GSR | |
| SCHEMBL26181037 | 0.80 | PTPN1 (0.59) | GSK3BPTPN1KMT2AMEN1GSR | |
| SCHEMBL125350 | 0.80 | GSR (0.59) | GSK3BPTPN1GSR | |
| SCHEMBL3642480 | 0.80 | CA2 (0.59) | GSK3BPTPN1 | |
| SCHEMBL205280 | 0.80 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL9647547 | 0.78 | GSR (0.45) | GSK3BKMT2AALDH1A1HSD17B10TDP1 | |
| SCHEMBL7550413 | 0.78 | GSK3B (0.50) | GSK3BPTPN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15229332 | 0.77 | GSK3B (0.64) | GSK3BPTPN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL7917653 | 0.76 | ALDH1A1 (0.50) | KMT2AALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | SCHMITZ FRANZ ULRICH | 2010-01-07 | — | — | US | disclosed |
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1971597-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-4125614-A | DIURETIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-4061761-A | Thiazolidine derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, HAVCR2 | GSK3B 4064/4885PTPN1 2198/4885KMT2A 2419/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | GSK3B 4064/4885PTPN1 2198/4885KMT2A 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.